Related Experiment Video
Updated: Jun 16, 2026
05:58
Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model
Published on: April 18, 2025
Fluvastatin attenuates diabetes-induced cardiac sympathetic neuropathy in association with a decrease in oxidative
Akira Matsuki1, Takashi Nozawa, Norio Igarashi
1Second Department of Internal Medicine, Graduate School of Medicine, University of Toyama, 2630 Sugitani, Toyama 930-0194, Japan.
Summary
Flutvastatin treatment improved cardiac sympathetic neural function in diabetic rats by reducing oxidative stress. This study investigated fluvastatin
Area of Science:
- Cardiovascular Research
- Metabolic Disorders
- Pharmacology
Background:
- Diabetic neuropathy is linked to increased oxidative stress.
- The study investigates fluvastatin's effects on diabetic rat hearts.
Purpose of the Study:
- To assess fluvastatin's impact on myocardial oxidative stress.
- To evaluate its effect on cardiac sympathetic neural function in diabetic rats.
Main Methods:
- Streptozotocin-induced diabetic rats received fluvastatin or vehicle for 2 weeks.
- Cardiac oxidative stress markers (8-iso-prostaglandin F(2alpha), p22(phox) mRNA) were measured.
- Cardiac sympathetic function was assessed using (131)I-metaiodobenzylguanidine (MIBG) autoradiography.
Main Results:
- Flutvastatin did not alter glucose levels but significantly reduced oxidative stress markers.
- Cardiac (131)I-MIBG uptake was improved in fluvastatin-treated diabetic rats.
- Reduced MIBG uptake in diabetic rats was linked to impaired neural function, not clearance.
Conclusions:
- Flutvastatin ameliorates cardiac sympathetic neural dysfunction in diabetic rats.
- This improvement is associated with reduced myocardial oxidative stress.
Related Concept Videos
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
01:30Coronary Artery Disease I: Introduction
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
01:30Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
01:28Diabetic Nephropathy
Definition Diabetic nephropathy is a chronic kidney complication that results from prolonged hyperglycemia.Prevalence It is the most common cause of chronic kidney disease (CKD) and end-stage renal disease (ESRD) worldwide, affecting up to half of individuals with diabetes.Pathophysiology • Sustained hyperglycemia triggers multiple hemodynamic and metabolic changes in the kidney. • Early in the disease, increased renal blood flow and glomerular hyperfiltration occur due to afferent arteriolar...